Dagrafors Duo

Dagrafors Duo combines sitagliptin and dapagliflozin for oral use, offering a dual approach to managing certain health conditions. This medication is designed to support metabolic health and may be prescribed for adults requiring combination therapy.

Dagrafors Duo is a combination of sitagliptin and dapagliflozin, two medications often used together to manage type 2 diabetes. Sitagliptin works by increasing insulin levels, while dapagliflozin helps the kidneys remove excess glucose from the body. This dual-action approach is intended to help control blood sugar levels in adults with type 2 diabetes who need combination therapy. The medication is not suitable for everyone, and its use should be determined by a healthcare professional.

Common effects of Dagrafors Duo may include symptoms such as nausea, diarrhea, and urinary tract infections. Some individuals may also experience dizziness or low blood sugar, especially when starting the medication or adjusting the dose. These effects can vary from person to person, and not everyone will experience them. If any effects are severe or persistent, it is important to consult a healthcare professional.

Dagrafors Duo should be handled with care, especially for individuals with a history of kidney problems, pancreatitis, or allergic reactions to similar medications. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Regular monitoring of blood sugar levels and kidney function may be necessary while using this medication.

Dagrafors Duo may interact with certain medications, including insulin, other diabetes medications, and drugs that affect kidney function. Alcohol consumption should be limited, as it can affect blood sugar levels and increase the risk of side effects. It is important to inform a healthcare professional about all medications and supplements being taken to avoid potential interactions.